Document is current
Any future updates will be listed below
-
Authors
Bonfiglioli, Karina Rossi https://orcid.org/0000-0003-3547-5674
de Medeiros Ribeiro, Ana Cristina https://orcid.org/0000-0001-7168-5906
Carnieletto, Ana Paula
Pereira, Ivânio https://orcid.org/0000-0002-3910-4988
Domiciano, Diogo Souza https://orcid.org/0000-0001-7991-0231
da Silva, Henrique Carriço https://orcid.org/0000-0001-5665-4650
Pugliesi, Alisson https://orcid.org/0000-0003-0444-738X
Pereira, Leticia Rocha https://orcid.org/0000-0002-9899-1695
Guimarães, Maria Fernanda Resende https://orcid.org/0000-0003-3865-3739
Giorgi, Rina Dalva Neubarth https://orcid.org/0000-0002-0921-1723
Reis, Ana Paula Monteiro Gomides https://orcid.org/0000-0003-2884-2210
Brenol, Claiton Viegas https://orcid.org/0000-0003-0229-7912
Louzada-Júnior, Paulo https://orcid.org/0000-0003-2585-3870
da Cunha Sauma, Maria de Fátima Lobato
Radominski, Sebastião Cezar https://orcid.org/0000-0001-6366-8401
da Mota, Licia Maria Henrique https://orcid.org/0000-0002-8182-5121
da Rocha Castelar-Pinheiro, Geraldo https://orcid.org/0000-0002-7778-569X
-
Funding
Funding for this research was provided by:
Sociedade Brasileira de Reumatologia
- License Information
-
More Information
Article History
Received: 16 January 2023
Accepted: 19 July 2023
First Online: 26 July 2023
Declarations
:
: The REAL Study received ethical approval from the Universidade do Estado do Rio de Janeiro (the coordinating centre) Research Ethics Committee (registration number 45781015.8.1001.5259). Each participating site also obtained approval from their respective institution’s ethics committee. All patients consented to participation in the study.
: All authors have read and approved the final version of this manuscript.
: ACMR: Personal fees and/or nonfinancial support from Janssen, Pfizer, and AstraZeneca. AP: Personal fees and/or nonfinancial support from Pfizer, AbbVie, UCB, BMS, Janssen, Lilly, Boehringer-Ingelheim. APC: No conflicts declared. APMG: Assistance for participation in events: Pfizer; CVB: personal or institutional support from AbbVie, Janssen and Pfizer; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Bristol-Myers Squibb and UCB. DSD: Personal fees and/or non-financial support from Pfizer, UCB, AbbVie. GRCP: No conflicts declared. HCS: No conflicts declared. IAP: personal fee for lectures at AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Boehringer- Ingelheim, Janssen, Pfizer, Roche, Sandoz, Lilly and UCB. KRB: personal fees and/or nonfinancial support from Pfizer, AbbVie, Roche, Novartis, Boehringer-Ingelheim. LRP: No conflicts declared. LMHM: personal or institutional support from AbbVie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Boehringer-Ingelheim, Janssen, Pfizer, Roche, Sandoz, Lilly and UCB. MFBRG: personal fees and/or non-financial support from AbbVie, Bristol-Myers-Squibb, Janssen, Novartis, Pfizer, Roche and UCB. MFLCS: No conflicts declared. PL-J: Sponsored by Bristol-Myers Squibb, UCB, Pfizer, board Participation: Pfizer. RDNG: consulting fees, speaking fees, and support for international congresses from Roche, Pfizer, Bristol-Myers-Squibb, UCB Pharma, Eli-Lilly, AbbVie, Abbott, and EMS. SCR: Consulting fees, speaking fees, and support for clinical trials from AbbVie, Amgen, Bristol-Myers-Squibb, Lilly, Pfizer, and Roche.
